ASK120067 (limertinib) exerts pre-clinical anti-tumor activity by inhibiting EGFR exon20 insertion
Cited by 3
Related Papers
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
|Molecular Cancer|2020|143
A Novel IRAK4 Inhibitor DW18134 Ameliorates Peritonitis and Inflammatory Bowel Disease
|Molecules|2024|5
ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK
|Frontiers in Pharmacology|2022|1